ClinicalTrials.gg
Active, not recruitingNCT05356195Updated Jul 1, 2026

Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)

A Phase 3 interventional study of CTX001 in Beta-Thalassemia, Thalassemia and Genetic Diseases, Inborn, sponsored by Vertex Pharmaceuticals Incorporated. Active, not recruiting at 6 sites in 5 countries. Open to participants aged 2 Years to 11 Years. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
2 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in beta-Thalassemia with a site in United Kingdom — 2 open to participants now, 7 under way, 5 of them phase 3. beta-Thalassemia · United Kingdom.

Enrollment
17th of 18
16 · median 72
Started
2022
with 1 other
Phase 3
9 of 19
2 open now
Registered
18th of 19
by date
Lead sponsor
3 of 19
Vertex Pharmaceuticals Incorporated

Among the 19 studies in beta-Thalassemia with a site in United Kingdom, this one is the 17th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2022, is one of 9 in phase 3, and was the 18th registered.

beta-Thalassemia

294 studies on the registry are indexed under beta-Thalassemia; 69 are open to participants now.

Browse beta-Thalassemia studies →

Open to participants now

2 of the 19 studies in beta-Thalassemia with a site in United Kingdom are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 43 beta-Thalassemia studies recruiting now, 10 (23%) set no upper age limit and 31 (72%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.

This study: 2 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in beta-Thalassemia with a site in United Kingdom, or all of them as a file.
02

Study summary

This is a single-dose, open-label study in pediatric participants with TDT. The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (CTX001).

03

Conditions studied

  • Beta-Thalassemia
  • Thalassemia
  • Genetic Diseases, Inborn
  • Hematologic Diseases
  • Hemoglobinopathies
04

Who can participate

Ages eligible
2 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosis of TDT as defined by:

    • Documented homozygous or compound heterozygous β-thalassemia including β-thalassemia/ E (HbE). Participants can be enrolled based on historical data, but a confirmation of the genotype using the study central laboratory will be required before busulfan conditioning
    • History of at least 100 mL/kilograms (kg)/year of packed RBC transfusions in the prior 24 months before signing of consent (or the last rescreening for patients going through repeat screening) or, for participants initiating transfusion therapy \<24 months before signing of consent, requirement for packed RBC transfusion at least every 3 to 4 weeks for ≥6 months
  • Eligible for stem cell transplant as per investigator's judgment.

Key Exclusion Criteria:

  • A willing and healthy 10/10 human leukocyte antigen (HLA)-matched related donor is available per investigator's judgement
  • Prior hematopoietic stem cell transplant (HSCT)
  • Participants with associated α-thalassemia and >1 alpha deletion, or alpha multiplications
  • Participants with sickle cell β-thalassemia variant
  • and active bacterial, viral, fungal, or parasitic infection as determined by the investigator

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    CTX001

    CTX001 (autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the erythroid lineage-specific enhancer of the BCL11A gene). Participants will receive single infusion of CTX001 through central venous catheter.

    Biological: CTX001

Interventions

  • BiologicalCTX001

    Administered by intravenous infusion following myeloablative conditioning with busulfan.

    Also known as: Exagamglogene autotemcel, Exa-cel

06

What researchers measure

Primary outcomes

  1. Proportion of Participants who Achieve Transfusion Independence for at Least 12 Consecutive Months (TI12)

    Time frame: Up to 24 Months After CTX001 Infusion

Secondary outcomes

  1. Proportion of Participants Achieving at Least 95 Percent (%), 90%, 85%, 75% and 50% Reduction in Annualized Transfusions

    Time frame: From Baseline up to 24 Months After CTX001 Infusion

  2. Transfusion Free Duration for Participants who Achieve TI12

    Time frame: Up to 24 Months After CTX001 Infusion

  3. Proportion of Alleles With Intended Genetic Modification Present in Peripheral Blood Over Time

    Time frame: Up to 24 Months After CTX001 Infusion

  4. Proportion of Alleles With Intended Genetic Modification Present in CD34+ Cells of the Bone Marrow Over Time

    Time frame: Up to 24 Months After CTX001 Infusion

  5. Change in Fetal Hemoglobin Concentration Over Time

    Time frame: From Baseline (Pre-transfusion) up to 24 Months After CTX001 Infusion

  6. Change in Total Hemoglobin Concentration Over Time

    Time frame: From Baseline (Pre-transfusion) up to 24 Months After CTX001 Infusion

  7. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From Signing of Informed Consent up to 24 Months After CTX001 Infusion

  8. Proportion of Participants With Engraftment (First day of 3 Consecutive Measurements of Absolute Neutrophil Count [ANC] ≥500 per Microliter [mcgL] on 3 Different Days)

    Time frame: Within 42 Days After CTX001 Infusion

  9. Time to Engraftment

    Time frame: Up to 24 Months After CTX001 Infusion

  10. Incidence of Transplant-related Mortality (TRM) Within 100 Days After CTX001 Infusion

    Time frame: Within 100 Days After CTX001 Infusion

  11. Incidence of TRM Within 12 Months After CTX001 Infusion

    Time frame: Within 12 Months After Infusion

  12. Incidence of All-cause Mortality

    Time frame: From Signing of Informed Consent up to 24 Months After CTX001 Infusion

  13. Relative Reduction in Annualized Volume and Episodes of RBC Transfusions starting Month 10 After CTX001 infusion

    Time frame: From Baseline up to 24 Months After CTX001 Infusion

07

Study locations

6 sites
08

References and documents

Publications

  • Frangoul H, de la Fuente J, Chopra Y, Meisel R, Amrolia PJ, Algeri M, Sharma A, Cappellini MD, Corbacioglu S, Kattamis A, Lobitz S, de Montalembert M, Rondelli D, Sheth S, Steinberg MH, Walters MC, Boerner K, Liu T, Zairis S, Hobbs W, Grupp SA, Locatelli F; CLIMB THAL-141 and CLIMB SCD-151 Study Groups. Exa-cel in Children with Transfusion-Dependent beta-Thalassemia or Sickle Cell Disease. N Engl J Med. 2026 Jun 11. doi: 10.1056/NEJMoa2603387. Online ahead of print. PubMed 42274009 ↗

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Nov 2027, 66 months after the start.

Of 18 phase 3 interventional studies under beta-Thalassemia, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 67. This study's planned 66 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2022
First posted
May 2, 2022
StartActual
May 3, 2022
Primary completionEst.
Nov 14, 2027
CompletionEst.
Nov 14, 2027
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05356195
Collaborators
CRISPR Therapeutics
Responsible party
Sponsor
First posted
May 2, 2022
Start date
May 3, 2022
Primary completion
Nov 14, 2027 (estimated)
Completion
Nov 14, 2027 (estimated)
Last update
Jul 1, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Exagamglogene autotemcel

Start the discussion